Effective September 1, 2021, the Medicare Advantage Plans medical criteria for brand name test Decipher, used for gene expression profiling and protein biomarkers for prostate cancer management, will be revised based on available Centers for Medicare and Medicaid Services (CMS) local coverage determination (LCD) guidance. The test remains not medically necessary for commercial products. Please refer to the medical policy for details by clicking here.